Guardant Health Inc

Guardant Health Inc

GH

Get informed when a big investor buys or sells

+ Follow
Market Cap$21.48B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Guardant Health IncGuardant Health Inc-46.4-203%20.2-7.7

Earnings Call Q2 2026

July 30, 2026 - AI Summary

Strong Q2 growth across all segments (good): - Revenue: $335M, +44% YoY (broad-based: Oncology, Biopharma & Data, Screening). - Oncology: $219M, +38% YoY; ~104k tests, +63% YoY. - Guardant360 Liquid: >30% YoY growth (Smart app adoption). - Guardant360 Tissue: accelerated; second-fastest growing product. - Reveal (MRD/therapy monitoring): >100% YoY volume growth; strong ramp and therapy monitoring contributing meaningfully. - Biopharma & Data: $61M, +9% YoY (record quarter); growing companion diagnostic franchise (28 CDx approvals, 4 added in 1H 2026). - Screening (Shield): $53M, +~3.3x YoY (from ~$15M); ~66k tests (from ~16k).
Major product/regulatory catalysts (surprising + opportunity): - FDA approval of Guardant360 Liquid CDx (May 2026): integrates genomic + epigenomic (methylation/epigenomic content); major milestone; phased rollout already started. - Guardant360 Liquid CDx ADLT expected in H1 2027 (enables Medicare Advantage/commercial repricing). - FDA approval for higher-throughput, lower-COGS Shield workflow (June; live in production August): expected to reduce Shield cost/test (step-down initially) and improve lab scalability. - Shield commercial acceptance: included in American Cancer Society CRC guidelines; UnitedHealth Group coverage decision (effective Aug 1) for ages 45+ (primary CRC screening option).
2026 guidance raised (good) with clear demand + cost trajectory: - Full-year revenue guidance: raised to $1.34B–$1.36B (+36% to +38% YoY). - Oncology: now expects ~30% revenue growth and ~50% volume growth (portfolio strength across Liquid/Tissue/Reveal despite tougher comps). - Screening (Shield): raised to $218M–$230M and 270k–285k Shield tests (confidence increased after ACS inclusion + UnitedHealth coverage starting Aug 1). - Gross margin (non-GAAP): outlook maintained at 64%–65% (lower testing costs partially offset by mix; Shield + Reveal scaling). - OpEx: $1.08B–$1.1B (+20% to +22% YoY), reflecting expanded Screening commercialization investment. - Free cash flow: expects burn $195M–$205M (about $10M worse vs prior, driven by additional CapEx to expand Shield lab capacity); committed to cash flow breakeven by end of 2027.

Exclusive for Stockcircle Pro members

Sign upSign Up
$176.75

Target Price by Analysts

9.1% upsideGuardant Health Target Price DetailsTarget Price
$-139.53

Current Fair Value

186.1% downside

Overvalued by 186.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$21.48 Billion
Enterprise Value$22.14 Billion
Dividend Yield$- (-)
Earnings per Share$-3.32
Beta1.59
Outstanding Shares132,074,000

Return

Return on Equity203.46%ROE
Return on Assets-23.71%
Return on Invested Capital-28.82%

Valuation & Multiples

P/E Ratio-46.42P/E Ratio
PEG-229.06PEG
Price to Sales20.25Price to Sales
Price to Book Ratio-81.0Price to Book Ratio
Enterprise Value to Revenue18.71
Enterprise Value to EBIT-48.82
Enterprise Value to Net Income-49
Total Debt to Enterprise0.08
Debt to Equity-7.69Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
July 30, 2026
EPS Estimate
$-0.76
Average shareholder expectation
Revenue Estimate
$314.23 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 28, 2026
EPS Estimate
$-0.28
Average shareholder expectation
Revenue Estimate
$346.53 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000 153.59%
Total Calls- 100.00%
Total Puts94,800 91.83%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.22% 104.54%
Total Invested$445.42M 96.44%
Investors Holding154 351.00%

ESG Score

No data

About Guardant Health Inc

Relevant Senate Committees

Joint Committee on Taxation

This committee provides the official revenue estimates and technical analysis for all tax legislation, directly influencing corporate tax structures and the overall tax burden on manufacturing companies like dental laboratories.

Finance

As the primary tax-writing committee, it directly impacts corporate valuations through tax policy. Trade policy (tariffs on imported materials) can also significantly affect the cost of goods for a manufacturing dental laboratory.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA, which oversees medical devices, including dental prosthetics and materials. Its influence on labor laws also directly impacts manufacturing costs and operations for a dental laboratory.

Judiciary

This committee's jurisdiction over antitrust laws and intellectual property (patents for new materials or processes) is critically important for manufacturing companies like dental laboratories, directly influencing competition and innovation.

Veterans' Affairs

The Department of Veterans Affairs is a major healthcare provider. This committee's funding decisions directly impact government healthcare contractors, including dental laboratories that may supply or service veterans' dental care needs.

Commerce, Science, and Transportation

With vast jurisdiction over interstate commerce, this committee impacts manufacturing through general safety regulations, competition policy (FTC), and potential R&D in dental materials. It directly influences how products are made and sold across state lines.